Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. (PubMed, Drug Des Devel Ther) - Oct 5, 2026 - "Samples were subjected to tryptic digestion and analyzed in multiple reaction monitoring (MRM) mode, with rituximab as a full-process internal standard. The developed LC-MS/MS method provides a practical, specific, and reproducible tool for the multiplex quantification of therapeutic mAbs. Based on a preliminary exploratory study of 37 patient samples, this method demonstrates analytical feasibility and serves as a promising tool for pharmacokinetic research; however, its definitive clinical applicability and readiness for routine TDM require further confirmation through cross-platform comparison, incurred sample reanalysis, and external validation in larger cohorts."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease
|
|
Limei Li; Na Wang; Ruichen Liu; Weiyang Zheng; Xianglong Zhao; Xiaohong Han; Xin Zheng; Yanbao Zhang
|